Skip to main content

Fiscal Wizard · Single-issue tearsheet

SNDX / Jun 20, 2026 Run #7213

SNDX

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Composite verdict

F 21.9 / 100
Bearish setup · Reversal 11 drivers · 8 gates blocking
  • MA Rejection
  • Connors RSI(2)
  • Double 7s
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 248th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 15 signals100% Bear
Momentum Bearish 14Mean-reversion Bearish 37

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

43.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Asset Turnover 84
Inventory Turnover 0
Gross Margin 75
Cash Conversion Cycle 0

Technicals Bearish

0.0 / 100

Bearish setup leads (MA Rejection, Connors RSI(2), Double 7s); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MA Rejection 11
Connors RSI(2) 17
Vortex Signal 17

Risk Gates

8 blocking 5 caution

8 guards active, 26 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SNDX.